The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Coronary interventions

Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial

EuroIntervention 2019;15:e269-e278. DOI: 10.4244/EIJ-D-18-00247

1. Department of Cardiology, Bern University Hospital, Bern, Switzerland and Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy; 2. Institute of Primary Health Care (BIHAM), University of Bern, Switzerland, and Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Canada; 3. Department of Cardiology, Bern University Hospital, Bern, Switzerland; 4. Ospedale Pasquinucci, Massa, Italy; 5. San Camillo-Forlanini, Rome, Italy; 6. Ospedale Sacra Famiglia Fatebenefratelli, Erba, Fatebenefratelli, 22036 Como CO, Italy.; 7. Citta’ di Lecce Hospital, Lecce, Italy; 8. Casa Sollievo della Sofferenza, San Giovanni Rotodondo Foggia, Viale Cappuccini, 1, 71013 San Giovanni Rotondo FG, Italy; 9. A.O. Civili Riuniti - Giovanni Paolo II - Sciacca; 10. Ospedale San Jacopo, Pistoia, Italy; 11. Thoraxcenter, Erasmus Medical, Center, Rotterdam, Netherlands; 12. Azienda Ospedali Riuniti-Presidio GM Lancisi, Ancona, Italy; 13. Ospedale San Giuseppe Moscati, Avellino AV, Italy; 14. Ospedale Maggiore, Lodi LO, Italy; 15. Università degli Studi G d’Annunzio Chieti e Pescara, Chieti, Italy; 16. A.O.U. San Giovanni Battista Molinette di Torino, Turin, Italy; 17. Department of Cardio-Thoracic and Vascular Diseases, San Raffaele Scientific Institute, Milan, Italy; 18. Ospedale Civile di Mirano, Via Zinelli, 30035, Mirano Venezia VE, Italy; 19. Ospedali Riuniti Padova Sud, Monselice PD, Italy; 20. Clinic Cardiovascular Institute, University Hospital Clinic, IDIBAPS (Institut d'Investigacions Biomèdiques August Pi i Sunyer), Barcelona, Spain; 21. A.O. U. San Luigi Gonzaga di Orbassano Turin, Italy;; 22. Ospedale San Francesco, Nuoro, Italy; 23. Azienda USL Reggio Emilia; 24. Ospedali Riuniti ASL 17, Savigliano (CN), Italy; 25. Ospedale San Donato, Arezzo, Italy; 26. AORN Cardarelli, Napoli, Italy; 27. Maastricht University Medical Center, and Zuyderland MC, The Netherlands; 28. Sahlgrenska University Hospital, Göteborg, Sweden; 29. A.O.Spedali Civili, Brescia, Italy; 30. Hospital Marques de Valdecilla, Santander, Spain; 31. Ospedale Civile di Legnano, Legnano, Italy; 32. Ospedale Santo Spirito in Saxia, Roma, Italy; 33. From Department of Cardiology, Bern University Hospital, Bern, Switzerland; 34. Department of Cardiology, Bern University Hospital, Bern, Switzerland, Switzerland

Aims: Our aim was to assess whether bivalirudin compared with unfractionated heparin (UFH) is associated with consistent outcomes in males and females with acute coronary syndrome (ACS) undergoing invasive management.

Methods and results: In the MATRIX programme, 7,213 patients were randomised to bivalirudin or UFH. Patients in the bivalirudin group were subsequently randomly assigned to receive or not a post-PCI bivalirudin infusion. The 30-day co-primary outcomes were major adverse cardiovascular events (MACE), defined as death, myocardial infarction, or stroke, and net adverse clinical events (NACE), defined as MACE or major bleeding. The primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of urgent target vessel revascularisation (TVR), definite stent thrombosis (ST), or NACE. The rate of MACE was not significantly lower with bivalirudin than with heparin in male (rate ratio [RR] 0.90, 95% confidence interval [CI]: 0.75-1.07; p=0.22) and female patients (RR 1.06, 95% CI: 0.80-1.40; p=0.67) without significant interaction (pint=0.31), nor was the rate of NACE (males: RR 0.85, 95% CI: 0.72-1.01; p=0.07; females: RR 0.98, 95% CI: 0.76-1.28; p=0.91; pint=0.38). Post-PCI bivalirudin infusion, as compared with no infusion, did not significantly decrease the rate of urgent TVR, definite ST, or NACE (males: RR 0.84, 95% CI: 0.66-1.07; p=0.15; females: RR 1.06, 95% CI: 0.74-1.53; p=0.74; pint=0.28).

Conclusions: In ACS patients, the rates of MACE and NACE were not significantly lower with bivalirudin than with UFH in both sexes. The rate of the composite of urgent TVR, definite ST, or NACE was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion in both sexes.

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
The effectiveness of excimer laser angioplasty to treat coronary in-stent restenosis with peri-stent calcium as assessed by optical coherence tomography